Alkermes plc on Monday released topline results Monday from its Phase 1 proof-of-concept study evaluating ALKS 7290, an investigational orexin 2 receptor agonist designed to treat attention-deficit ...

A novel orexin-2 receptor agonist showed ‘clinically meaningful’ outcomes in adult ADHD in a new phase 1B study, making it one of the first of its class to show such a signal.

The next evolution in ADHD therapy needs to focus not only on drug efficacy but also on how treatment aligns with the ...

Natural remedies for attention deficit hyperactivity disorder (ADHD), such as diet or lifestyle changes, can help people to manage the impulsive behavior, lack of focus, and other traits associated ...

DUBLIN--Alkermes plc (Nasdaq: ALKS) today announced positive topline results from a phase 1 proof-of-concept study evaluating ALKS 7290, the company’s novel, investigational orexin 2 receptor (OX2R) ...

If you've had difficulty concentrating due to the stress of the past few years, you're not alone. Occasional disorganization, poor planning, and restlessness are a normal part of life, especially this ...

Alkermes stock jumped Monday on the first proof-of-concept for its orexin-modulating drug in adults with ADHD.

Do ADHD meds stunt growth? A new 30-year study tracking more than 64,000 children found stimulants have a negligible effect on adult height.

A new review conducted by Polish investigators showed that evidence obtained using various modalities has taken center stage ...

ADHD symptoms in girls differ due to menstrual cycle hormones that impact inattention and impulsivity, according to new research on sex differences in ...

Estonia will ease prescribing rules for certain ADHD medications for children and young people from October 1, removing the requirement for psychiatrists to consult a treatment team before prescribing ...